Using Mupirocin Nasally in Healthy Volunteers
Pharmacology of Mupirocin in Nasal Application in Healthy Volunteers: Monocentric Study
PHASE1 · Centre Hospitalier Universitaire de Saint Etienne · NCT06368856
This study is testing how well mupirocin, an antibiotic, works when applied in the nose of healthy volunteers to see if it can help prevent infections.
Quick facts
| Phase | PHASE1 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Saint Etienne (other) |
| Locations | 1 site (Saint-Étienne) |
| Trial ID | NCT06368856 on ClinicalTrials.gov |
What this trial studies
This study investigates the pharmacology of mupirocin when applied nasally in healthy volunteers. Mupirocin is an antibiotic traditionally used for skin infections and is now part of a decolonization strategy for Staphylococcus aureus carriers, particularly before surgeries. Participants will receive different doses of mupirocin, and various samples will be collected to assess its pharmacokinetics and effectiveness. The study aims to better understand how mupirocin works in the nasal application and its potential role in preventing infections.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy volunteers who are affiliated with a social security plan and can provide informed consent.
Not a fit: Patients who are pregnant, have acute or chronic rhinorrhea, or have a history of significant medical conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance preoperative infection control strategies for patients undergoing surgery.
How similar studies have performed: Previous studies have shown the effectiveness of mupirocin in decolonization strategies, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject affiliated or entitled to a social security plan * Subject having signed the consent to participate in the study Exclusion Criteria: * Pregnancy in progress * Acute or chronic rhinorrhea * Allergy to mupirocin calcium or excipients * Any medication taken during the week preceding the beginning of the study * Notable medical history (cardiovascular, pulmonary, neurological pathology, etc.)
Where this trial is running
Saint-Étienne
- CHU de SAINT-ETIENNE — Saint-Étienne, France (RECRUITING)
Study contacts
- Principal investigator: Kasra AZARNOUSH, MD PhD — CHU SAINT-ETIENNE
- Study coordinator: Kasra AZARNOUSH, MD PhD
- Email: Kasra.Azarnoush@chu-st-etienne.fr
- Phone: (0)477829446
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Healthy, Staphylococcus Aureus Infection, Staphylococcus Aureus, Mupirocin, Pharmacokinetic